Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Editas Medicine Q3 2026 Results: Net Loss of $23.4M, Loss Narrows

Editas Medicine reported a net loss of $23.4 million for the third quarter of 2026, a significant improvement from the $154.4 million loss in the prior year period which was impacted by restructuring charges. The company strengthened its balance sheet through a $116.9 million common stock and warrant financing, ending the period with $190.2 million in cash, cash equivalents, and marketable securities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue10.47.5
Net income-23.4-25.1
EPS (diluted, $ a share)$-0.15$-0.28

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+37.4%
Operating margin-234.3%
Source

10-Q filed with the SEC, NASDAQ: EDIT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Editas Medicine, Inc.: key numbers

Share price
$1.87Close, Nov 16
Market cap
$289M
Shares outstanding
154.34MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Editas Medicine, Inc.

All →
4:35 PM ET Form 4
Insider Selling

Editas Medicine CEO Gilmore Neil O'Neill Sells $51.1K of Stock

Gilmore Neil O'Neill, CEO, sold 21,164 shares of Editas Medicine, Inc. at $2.42 a share, worth $51.1K in total on Nov 11, 2026. Shares held after the trade: 265,592 (-7.4%).

Value
$51.1K
Shares
21,164
Price
$2.42
Role
CEO
Holding change
-7.4%
Trade date
Nov 11, 2026
4:34 PM ET Form 4
Insider Selling

Editas Medicine EVP, CSO Linda Burkly Sells $18.9K of Stock

Linda Burkly, EVP, CSO, sold 7,814 shares of Editas Medicine, Inc. at $2.42 a share, worth $18.9K in total on Nov 11, 2026. Shares held after the trade: 70,379 (-10.0%).

Value
$18.9K
Shares
7,814
Price
$2.42
Role
EVP, CSO
Holding change
-10.0%
Trade date
Nov 11, 2026
7:05 AM ET 8-K
Financial Results

Editas Medicine Financial Results

Editas Medicine reported Q3 2026 financial results, highlighting a cash runway extending into the second half of 2028. The company received regulatory approval to initiate its Phase 1/2 Strive study for EDIT-401 in Australia and triggered a milestone payment from Bristol Myers Squibb following the acceptance of a second IND/CTA for their CAR T collaboration.

Term
Q3 2026

“We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing medicine for hyperlipidemia, towards the clinic.”

Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer
7:05 AM ET 8-K
Business Update

Editas Medicine Business Update

Editas Medicine received approval to initiate its Phase 1/2 Strive clinical trial for EDIT-401 in Australia, targeting patients with heterozygous familial hypercholesterolemia. The company expects to begin patient dosing in 2026 and report initial safety and tolerability data in the first quarter of 2027. Additionally, the company will present new preclinical data demonstrating durable LDL-C reduction at the AHA Scientific Sessions in November 2026.

Counterparty
Therapeutic Goods Administration

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.